Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20232151 | 1.00 | NPSR1 (0.44) | NPSR1PPARGPPARAHPGDNLRP1 | |
| SCHEMBL20232152 | 0.90 | ALDH1A1 (0.41) | NPSR1PPARGPPARAKDM4ESMN1; SMN2 | |
| SCHEMBL20225820 | 0.88 | PPARG (0.41) | NPSR1PPARGPPARAHPGDNLRP1 | |
| SCHEMBL20225802 | 0.88 | PPARG (0.41) | NPSR1PPARGPPARAHPGDNLRP1 | |
| SCHEMBL20232156 | 0.84 | MRGPRX4 (0.42) | SMN1; SMN2ALDH1A1THRATHRBLMNA | |
| SCHEMBL20230375 | 0.82 | MAPT (0.52) | NPSR1PPARGHPGDKDM4ESMN1; SMN2 | |
| SCHEMBL20230370 | 0.82 | MAPT (0.52) | NPSR1PPARGHPGDKDM4ESMN1; SMN2 | |
| SCHEMBL20230367 | 0.82 | MAPT (0.52) | NPSR1PPARGHPGDKDM4ESMN1; SMN2 | |
| SCHEMBL20231597 | 0.81 | PPARG (0.49) | NPSR1PPARGPPARAHPGDNLRP1 | |
| SCHEMBL20231600 | 0.81 | PPARG (0.39) | NPSR1PPARGPPARAHPGDNLRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192894-B2 | Cell impermeable coelenterazine analogues | PROMEGA CORPORATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200239475-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-07-30 | — | — | US | disclosed |
| US-10577370-B2 | Cell impermeable coelenterazine analogues | PROMEGA CORPORATION (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180155350-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192894-B2 | Cell impermeable coelenterazine analogues | SI, GLB1, MRPL21 | NPSR1 4588/4885PPARG 4037/4885PPARA 4583/4885 |
| US-10577370-B2 | Cell impermeable coelenterazine analogues | SI, GLB1, MRPL21 | NPSR1 4588/4885PPARG 4037/4885PPARA 4583/4885 |
| US-20200239475-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | SI, GLB1, MRPL21 | NPSR1 4588/4885PPARG 4037/4885PPARA 4583/4885 |
| US-20180155350-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | SI, GLB1, MRPL21 | NPSR1 4588/4885PPARG 4037/4885PPARA 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.